Journal of Clinical Endocrinology & Metabolism, Vol 48, 50-53, Copyright © 1979 by Endocrine Society

ARTICLES

Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man

M Sheppard, B Shapiro, B Pimstone, S Kronheim, M Berelowitz and M Gregory

The MCR and half-disappearance time of exogenously administered somatostatin have been measured during and after cessation of a constant infusion. Studies were performed on normal volunteers and patients with chronic liver disease and failure. Immunoreactive somatostatin was measured by a sensitive and specific RIA using an antiserum directed against the core of the molecule. Normal subjects had a mean MCR of 1949 +/- 250 ml/min (28.4 +/- 4.2 ml/min . kg BW) (mean +/- SEM), similar to values found in five patients with chronic liver disease. However, patients with chronic renal failure showed a highly significant (P less than 0.001) lowering of the MCR (501 +/- 32.7 ml/min or 7.8 +/- 0.6 ml/min . kg). The rate of disappearance of somatostatin after infusion was linear for 7-10 min, after which a much slower component was observed. In normal subjects, the t 1/2 of the first component varied from 1.1-3.0 min, in patients with liver disease it varied from 1.2-4.8 min, and in patients with chronic renal failure it varied from 2.6-4.9 min. Exogenously administered somatostatin is rapidly cleared in normal subjects and patients with chronic liver disease, but the MCR in end stage chronic renal failure is markedly lowered. The kidney may have a role in the metabolic clearance of exogenously administered somatostatin, or uremia may impair catabolism nonspecifically.

This article has been cited by other articles:

				U Hesse, D Ysebaert, and B de Hemptinne Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data Gut, December 1, 2001; 49(90004): iv11 - 20. [Abstract] [Full Text] [PDF]

				C Gouillat and J-F Gigot Pancreatic surgical complications--the case for prophylaxis Gut, December 1, 2001; 49(90004): iv29 - 35. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, R. Demott-Friberg, M. Russell-Aulet, C. Y. Bowers, P. Marbach, and A. L. Barkan Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E489 - E495. [Abstract] [Full Text] [PDF]

				M. A. Sheridan, J. D. Kittilson, and B. J. Slagter Structure-Function Relationships of the Signaling System for the Somatostatin Peptide Hormone Family Integr. Comp. Biol., April 1, 2000; 40(2): 269 - 286. [Abstract] [Full Text] [PDF]

				P. Goumas, S. Naxakis, A. Christopoulou, C. Chrysanthopoulos, V. Nikolopoulou, and H. P. Kalofonos Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea Oncologist, February 1, 1998; 3(1): 50 - 53. [Abstract] [Full Text]

				P. C Gotzsche, I. Gjorup, H. Bonnen, N. E. B. Brahe, U. Becker, and F. Burcharth Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis BMJ, June 10, 1995; 310(6993): 1495 - 1498. [Abstract] [Full Text]